TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Linical Co., Ltd. ( (JP:2183) ) has shared an announcement.
Linical Co., Ltd. reported a decline in its financial performance for the three months ended June 30, 2025, with net sales dropping by 10.3% year-on-year. The company experienced a loss in operating and ordinary income, as well as a negative profit attributable to the owners of the parent. Despite these results, Linical maintains its dividend forecast for the fiscal year ending March 31, 2026, indicating stability in shareholder returns.
More about Linical Co., Ltd.
Linical Co., Ltd. is a company listed on the Tokyo Stock Exchange, operating in the clinical research industry. The company provides services related to drug development and clinical trials, focusing on delivering comprehensive solutions to pharmaceutical companies.
Average Trading Volume: 16,574
Technical Sentiment Signal: Sell
Current Market Cap: Yen7.57B
Learn more about 2183 stock on TipRanks’ Stock Analysis page.